CNS
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Cybin High On Psychedelic-Based CYB003 For MDD
The company will initiate a Phase III program in mid-2024, testing the deuterated psilocybin analog as an adjunctive treatment for depression on top of SSRIs.
Mission Therapeutics Raises Funds For Parkinson’s Disease Protein Modulator
New funding for the UK biotech reflects growing interest in finding ways to remove dysfunctional proteins from the body.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.
Roche Looks To Defy The Odds In Parkinson’s Study
Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.
Acadia's Nuplazid Expansion Bid Bites The Dust
Nuplazid is a decent earner for the US biotech in psychosis caused by Parkinson’s disease but following previous failures in Alzheimer's and dementia, the drug has now proved a dud for treating the negative symptoms of schizophrenia.
Boehringer Marches On In Mental Health With Sosei Heptares Pact
The family-owned German firm's legacy lies in the cardiometabolic space but it has been building a pipeline across a range of neuropsychiatric diseases. The collaboration with Sosei Heptares, which has been sealed with a upfront payment of €25m, will focus on schizophrenia.
A Visual Trip Through The Psychedelic Pipeline
An infographic looking at the status and origins of 39 psychedelic drug development programs being pursued by 26 sponsors.
Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again
The US FDA wants to hold an advisory committee meeting for Lilly’s donanemab in early Alzheimer’s disease, which means approval will now occur after the expected Q1 decision date.
Amylyx Shocks With Announcement Of PHOENIX Trial Failure In ALS
Some previously bullish analysts expressed humility as the company said the Phase III study failed to show statistical significance for Relyvrio/Albrioza on primary or secondary endpoints.
MindMed Ready To Take LSD Therapy Into Phase III For Anxiety
Mind Medicine’s LSD product MM120 will move into Phase III in the second half of 2024 after it showed efficacy in generalized anxiety disorder out to 12 weeks with a single administration in Phase IIb.
Sumitomo Pharma To Cut 400 US Employees Amid Latuda LOE
After reducing 500 employees last year while reorganizing its subsidiaries in the US in the aftermath of patent expiration for its mainstay product Latuda, the Japanese firm has decided to move ahead with another rationalization affecting 400 employees there.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.